NCT02819921View on ClinicalTrials.gov

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

PHASE4TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

June 15, 2019

Conditions
Hot FlashesBreast Neoplasms
Interventions
DRUG

Desvenlafaxine succinate 100mg

Pristiq 100mg

DRUG

Desvenlafaxine succinate 50mg

Pristiq 50mg

DRUG

Placebo

Placebo

Trial Locations (3)

10408

National Cancer Center, Goyang-si

13620

Seoul National University Bundang Hospital, Seongnam-si

03080

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Korea Cancer Center Hospital

OTHER

collaborator

Pfizer

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02819921 - Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen | Biotech Hunter | Biotech Hunter